



Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 [Based on Japanese GAAP]

May 11, 2023

Name of Listed Company: Meiji Holdings Co., Ltd. Listed exchange: Prime Market, Tokyo Stock Exchange
Code Number: 2269 URL: www.meiji.com
Representative: Kazuo Kawamura, CEO, President and Representative Director
Inquiries: Masashi Tanaka, General Manager of Corporate Communication Dept.
Telephone: +81-3-3273-3917

Annual shareholders meeting: June 29, 2023

Submission of the securities report: June 29, 2023

Dividend payment commencement: June 7, 2023

Preparation of explanatory materials for full-term financial results: Yes

Holding of a briefing on full-term financial results: Yes (a briefing for analysts and institutional investors)

(Amounts are rounded down to the nearest million yen.)

1. Consolidated Financial Results for the Fiscal Year Ended March 2023

(April 1, 2022 to March 31, 2023)

1) Consolidated operating results (% of change from the previous fiscal year)

	Net Sales		Operating Profit		Ordinary Profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
For the fiscal year ended								
March 31, 2023	1,062,157	4.8	75,433	-18.8	74,160	-21.1	69,424	-20.7
March 31, 2022	1,013,092	-15.0	92,922	-12.4	93,985	-14.7	87,497	33.3

(Note) Comprehensive income: Fiscal year ended March 31, 2023: JPY 77,669 million (-28.7%)

Fiscal year ended March 31, 2022: JPY 109,008 million (27.8%)

	Profit per Share	Diluted Profit per Share	Return on Equity	Ordinary Profit/Total Assets	Operating Profit/Net Sales
	Yen	Yen	%	%	%
For the fiscal year ended					
March 31, 2023	247.39	—	10.0	6.6	7.1
March 31, 2022	303.62	—	13.5	8.6	9.2

(Reference) Share of profit of entities accounted for using equity method: Fiscal year ended March 31, 2023: JPY -2,186 million

Fiscal year ended March 31, 2022: JPY 1,550 million

(Note) A two-for-one common stock split was issued on April 1, 2023. Profit per share is calculated on the assumption that the stock split was conducted at the beginning of the previous consolidated fiscal year.

2) Consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
As of March 31, 2023	1,136,217	751,311	62.7	2,553.69
As of March 31, 2022	1,117,459	713,021	60.3	2,390.76

(Reference) Shareholders' equity: As of March 31, 2023: JPY 711,917 million

As of March 31, 2022: JPY 673,336 million

(Note) A two-for-one common stock split was issued on April 1, 2023. Net assets per share is calculated on the assumption that the stock split was conducted at the beginning of the previous consolidated fiscal year.

3) Consolidated cash flows

	Cash Flows from Operating Activities	Cash Flows from Investing Activities	Cash Flows from Financing Activities	Cash and Cash Equivalents at Year-End
For the fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2023	85,013	-36,788	-54,734	60,939
March 31, 2022	127,526	-27,614	-76,997	64,872

2. Dividends

	Cash Dividends Per Share					Total Cash Dividends (Annual)	Payout Ratio (Consolidated)	Dividends to Net Assets Ratio (Consolidated)
	1Q	2Q	3Q	Financial year end	Annual			
For the fiscal year ended	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
March 31, 2022	–	80.00	–	90.00	170.00	24,284	28.0	3.8
March 31, 2023	–	85.00	–	95.00	180.00	25,217	36.4	3.6
March 31, 2024 (Projected)	–	47.50	–	47.50	95.00		52.3	

(Note) A two-for-one common stock split was issued on April 1, 2023. For the fiscal years ended March 31, 2022 and 2023, the actual dividend amount before the stock split is shown. For the fiscal year ending March 31, 2024, the projected dividend amount after stock split is shown.

3. Forecasts of Consolidated Financial Results for the Fiscal Year Ending March 31, 2024

(April 1, 2023 to March 31, 2024)

(% of change from the previous fiscal year)

	Net Sales		Operating Profit		Ordinary Profit		Profit attributable to owners of parent		Profit per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
1st half	544,000	5.1	32,000	-25.9	31,500	-28.3	20,000	-40.1	71.27
Full year	1,102,000	3.8	78,000	3.4	75,500	1.8	51,000	-26.5	181.73

(Note) A two-for-one common stock split was issued on April 1, 2023. Profit per share in the forecast of consolidated financial results for the fiscal year ending March 31, 2024 takes into account the effect of this stock split.

Notes

- 1) Changes in significant subsidiaries during the current fiscal year under review (Changes in subsidiaries affecting the scope of consolidation): None
- 2) Changes in accounting policy, changes in accounting estimates, restatements
 1. Changes in accounting policy due to revisions of accounting standards: Yes
 2. Other changes in accounting policy: None
 3. Changes in accounting estimates: None
 4. Restatements: None
- 3) Number of shares outstanding (common stock)

1. Number of shares outstanding at end of period (including treasury stock)	As of Mar. 31, 2023	296,739,000 shares	As of Mar. 31, 2022	296,739,000 shares
2. Number of treasury stock at end of period	As of Mar. 31, 2023	17,959,272 shares	As of Mar. 31, 2022	15,097,998 shares
3. Average number of shares during period	As of Mar. 31, 2023	280,633,245 shares	As of Mar. 31, 2022	288,177,618 shares

(Note) A two-for-one common stock split was issued on April 1, 2023. Number of shares outstanding at end of period, number of treasury stock at end of period, average number of shares during period are calculated on the assumption that the stock split was conducted at the beginning of the previous consolidated fiscal year.

(Reference) Non-Consolidated Financial Results for the Fiscal Year Ended March 31, 2023**(April 1, 2022 to March 31, 2023)**1) Non-consolidated operating results (% of change from the previous fiscal year)

	Net Sales		Operating Profit		Ordinary Profit		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
For the fiscal year ended								
March 31, 2023	28,063	-18.8	23,176	-23.9	23,924	-23.0	28,336	-10.7
March 31, 2022	34,547	35.3	30,447	36.6	31,055	35.5	31,735	42.0

	Profit per Share	Diluted Profit per Share
	Yen	Yen
For the fiscal year ended		
March 31, 2023	100.97	—
March 31, 2022	110.12	—

(Note) 1. For the FYE March 31, 2022, the dividend paid from the operating companies increased to guarantee the dividend resources. Therefore, there are differences between the actual results in FYE March 31, 2023 and FYE March 31, 2022.

2. A two-for-one common stock split was issued on April 1, 2023. Profit per share is calculated on the assumption that the stock split was conducted at the beginning of the previous consolidated fiscal year.

2) Non-consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
As of March 31, 2023	369,173	238,387	64.6	855.11
As of March 31, 2022	391,413	246,042	62.9	873.60

(Reference) Shareholders' equity: As of March 31, 2023: JPY 238,387 million

As of March 31, 2022: JPY 246,042 million

* The earnings summary is not subject to audit.

* Forward-looking statements and other special notes

(Notice concerning forward-looking statements)

The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of these materials and reasonable assumptions made by the Company, and do not represent a commitment from the Company that they will be achieved. For earnings forecasts assumptions and other related items, refer to page 14 of *1. Qualitative Information 3) Forecasts for the Fiscal Year ending March 31, 2024*

(Explanatory material for financial results)

Explanatory materials for financial results are disclosed through TDnet together with these financial statements. This information also is posted on our website on the same day.

(Presentation material for conference call)

The briefing (on-site, online) for analysts and institutional investors is scheduled on May 15, 2023. The presentation materials are posted on our website today, on May 11, 2023. An audio recording of the briefing will be posted on the website later.

1. Qualitative Information

1) Explanation Concerning Operating Results

The Meiji Group is aiming at realizing both profit growth and sustainability activities in line with the basic concept of our 2023 Medium-Term Business Plan “Promote the Meiji ROESG®* Management Effectively”.

Below is the key issues of 2023 Medium-Term Business Plan.

1. Business strategy

Food segment

- Recover from the slump in our core business
- Accelerate growth in our business overseas

Pharmaceutical segment

- Strengthen vaccine business
- Expand CMO/CDMO business

Overall group

- Venture into new domains

2. Improve business management using ROIC effectively

3. Investing to grow business while constructing strong financial base

4. Promote the Meiji Group Sustainability 2026 Vision

*ROESG is a registered trademark for a management indicator developed by Kunio Ito, a professor at Hitotsubashi University.

In the FYE March 2023, the impact of COVID-19 on the global economy and domestic consumption trends combined with skyrocketing raw material and energy costs created a severe operating environment.

Under these circumstances, in the food segment, we implemented price hikes and changed product volumes in order to absorb higher raw materials costs and energy costs. We strengthened efforts to promote the value of various products, conduct aggressive marketing activities, and worked to expand sales of new products. Overseas, we expanded production and sales capacity in China. We expanded sales areas and our line of high value-added products.

In the pharmaceutical segment, we focused management resources in the infectious disease domain, one of the Meiji Group’s strengths, as we worked to strengthen our competitive advantage as a top company for vaccines and infectious disease drugs. Additionally, we advanced cost reduction efforts and the expansion of the overseas CMO/CDMO business. We applied our Group’s advanced technology, vast facilities, and solid track record in infectious diseases to enhance the ability to create new drugs.

These factors resulted in net sales of JPY 1,062.157 billion (up 4.8%, year on year), operating profit of JPY 75.433 billion (down 18.8%, year on year), and ordinary profit of JPY 74.160 billion (down 21.1%, year on year) during FYE March 2023. Profit attributable to owners of parent was JPY 69.424 billion (down 20.7%, year on year). ROE was 10.0%, and EPS was JPY 247.39.

Note that a two-for-one common stock split was issued on April 1, 2023. The above EPS is calculated on the assumption that the stock split was conducted at the beginning of the current consolidated fiscal year under review.

In the 2023 Medium-Term Business Plan, we introduced the Meiji ROESG[®]. In addition to outlining indicators for growth and profitability such as net sales and operating profit, the Meiji ROESG[®] combines ROE and ESG benchmarks with proprietary indicators for sustainability goals unique to the Meiji Group. We also added ROIC as a benchmark for capital productivity and efficiency. Fiscal year results against Medium-Term Business Plan KPI are as shown below.

	Results for the fiscal year ended March 31, 2022	Results for the fiscal year ended March 31, 2023	Initial targets for Medium-Term Business Plan (FYE March 2024)
Meiji ROESG [®]	12.3 point	13.8 point	13 point
Consolidated net sales	JPY 1,013.0 billion	JPY 1,062.1 billion	JPY 1,080.0 billion
Food segment	JPY 826.0 billion	JPY 865.6 billion	JPY 874.5 billion
Pharmaceutical segment	JPY 187.9 billion	JPY 197.2 billion	JPY 209.0 billion
Consolidated operating profit (margin)	JPY 92.9 billion (9.2%)	JPY 75.4 billion (7.1%)	JPY 120.0 billion (11.1%)
Food segment	JPY 75.9 billion	JPY 55.8 billion	JPY 102.0 billion
Pharmaceutical segment	JPY 18.6 billion	JPY 21.7 billion	JPY 18.5 billion
Overseas net sales	JPY 92.9 billion	JPY 120.0 billion	JPY 134.5 billion
ROIC	8.4%	6.3%	More than 10%
ROE	13.5%	10.0%	More than 11%

(Billions of yen)

For the fiscal year ended March 31	2022	2023	Change	Main factors for Change
Net sales	1,013.0	1,062.1	49.0	Details indicated on segment-specific overview
Operating profit	92.9	75.4	-17.4	Details indicated on segment-specific overview
Non-operating profit	5.3	4.6	-0.7	- Share of profit of entities accounted for using equity method (-1.5) - Foreign exchange gains (+0.3) - Interest income (+0.1) - Dividend income (+0.1)
Non-operating expenses	4.3	5.8	1.5	- Share of loss of entities accounted for using equity method (+2.1) - Business commencement expenses (+0.8) - Other (-1.4)
Ordinary profit	93.9	74.1	-19.8	—
Extraordinary income	50.7	29.6	-21.1	- Gain on sales of shares of subsidiaries and associates (-33.6) - Gain on sales of non-current assets (+16.2)
Extraordinary losses	16.3	8.3	-7.9	- Loss on tax purpose reduction entry of non-current assets (-8.4)
Profit before income taxes	128.4	95.4	-33.0	—
Income taxes-total	36.0	23.9	-12.1	- Income taxes - current (-7.5) - Income taxes - deferred (-4.5)
Profit (loss) attributable to non-controlling interests	4.8	2.0	-2.8	—
Profit attributable to owners of parent	87.4	69.4	-18.0	—

The Meiji Group is engaged in the following initiatives for development of inactivated vaccine and next generation mRNA vaccine for COVID-19. We continue working towards early provision.

Currently, Group subsidiaries KM Biologics and Meiji Seika Pharma are developing an inactivated vaccine for COVID-19. We started Phase III clinical trials, the final stage prior to approval, in April 2022 (multi-regional clinical trials, adults under 40 years of age). We also started Phase III domestic pediatric clinical trials (children 6 months to less than 12 years of age) in January 2023.

In April 2023, Meiji Seika Pharma and CSL Seqirus, a subsidiary of CSL Limited, have entered into a distribution agreement for the distribution and sales of ARCT-154, a next generation mRNA COVID-19 vaccine, in Japan. CSL Seqirus has exclusively licensed worldwide rights to the vaccine, ARCT-154, from Arcturus Therapeutics Inc. Meiji Seika Pharma submitted a New Drug Application to manufacture and market ARCT-154 for primary immunization to prevent COVID-19 in adults (two doses of ARCT-154) in Japan.

Also, regarding the COVID-19 vaccine of AstraZeneca PLC, allocated for Japan, Meiji Seika Pharma is collecting safety management information of the COVID-19 vaccine.


The status of operations by segment and business are as follows.

(1) Food segment

- Net sales increased year on year. Net sales of overseas business and other and domestic subsidiaries increased significantly year on year. Net sales of nutrition business, chocolate and gummy business, B to B business increased year on year. Net sales from frozen dessert and ready meal business were largely unchanged. Net sales of yogurt and cheese business, and drinking milk business decreased year on year.
- Operating profit decreased significantly year on year, due to higher raw material costs and energy costs, as well as decreased sales volume in the yogurt and cheese business, even though we raised price for our mainstay products.

(Billions of yen)

For the fiscal year ended March 31	2022	2023	% Change
Net sales	826.0	865.6	4.8%
Operating profit	75.9	55.8	-26.5%



Below is an overview of each of food segment's main businesses.

(Billions of yen)

Net sales				Operating profit			
For the fiscal year ended March 31	2022	2023	% Change	For the fiscal year ended March 31	2022	2023	% Change
Yogurt & cheese	209.7	202.5	-3.5%	Yogurt & cheese	34.9	24.1	-30.9%
Nutrition	109.6	116.8	6.6%	Nutrition	19.3	14.6	-24.5%
Chocolate & gummy	98.0	102.8	4.9%	Chocolate & gummy	12.6	11.1	-11.8%
Drinking milk	76.1	71.5	-6.1%	Drinking milk	-0.7	-2.5	—
B to B	65.8	71.1	8.2%	B to B	2.7	3.0	12.8%
Frozen dessert& ready meal	58.2	57.9	-0.5%	Frozen dessert& ready meal	2.9	3.2	10.1%
Overseas	52.6	68.5	30.3%	Overseas	-1.0	-0.9	—
Other/ domestic subsidiaries	155.7	174.1	11.8%	Other/ domestic subsidiaries	5.0	3.0	-38.9%

■ Yogurt & cheese business (Probiotic yogurt, yogurt, cheese)

- Net sales decreased year on year. For functional yogurt and yogurt, we expanded our product line and strengthened marketing activities but sales decreased due to the impact of various competitor products appealing health value. Additionally, sales of cheese decreased since we reduced the number of items.
- Operating profit decreased significantly year on year due to the impact of the sales decrease and the increase in raw material costs, energy costs and marketing expenses.

■ Nutrition business (Infant formula, sports nutrition, enteral formula, beauty supplement)

- Net sales increased year on year. Sales of liquid diet *Meiji Mei Balance* and infant formula in which we caught inbound demand, were favorable. Sales of sports protein *SAVAS* were also favorable particularly for ready-to-drink products. As a result, overall net sales of *SAVAS* increased year on year.
- Operating profit decreased significantly year on year. The raw material costs and energy costs increased, and also depreciation costs increased due to production lines expansion.

■ Chocolate & gummy business

- Net sales increased year on year. Sales were favorable for our mainstay product *Chocolate Kouka*, and *Kinoko no Yama* and *Takenoko no Sato* series. Sales of gummy, which the market continues to expand, increased significantly year on year through introduction of new products and stronger marketing.
- Operating profit decreased significantly year on year due to the higher raw material costs and energy costs.

- Drinking milk business
 - Net sales decreased year on year. Sales were impacted by the reduction in the number of products offered and the decrease in sales of home delivery.
 - Operating profit decreased year on year. In addition to the higher raw material costs and the decline in net sales, depreciation costs increased due to the operation of a new plant.

- B to B business
 - Net sales increased year on year. Restaurant and gift confectionery demand recovered from the same period of the previous fiscal year, which was impacted by restrictions on movement due to the state of emergency declaration. In such circumstances, net sales increased significantly mainly on butter, ice cream and chocolate for professional use.
 - Operating profit increased significantly year on year due to increase in sales, even though there was an impact of higher raw material costs.

- Frozen dessert & ready meal business (Ice cream, prepared foods, butter and margarine)
 - Net sales were largely unchanged from the previous fiscal year. Sales of ice cream increased since the sales of our mainstay product *Essel Super Cup* and the new product *Bulgaria Frozen Yogurt Dessert* were favorable. However, sales of prepared foods decreased.
 - Operating profit increased significantly year on year. The impact of the increase in raw material costs were offset by price hikes. The decrease in manufacturing overhead also contributed.

- Overseas business (Overseas subsidiaries, exports)
 - Net sales increased significantly year on year, partly due to the positive valuation effect of yen depreciation. Net sales of confectionery business and ice cream business in China and subsidiaries in Southeast Asia and the US were favorable.
 - Operating losses were less than the same period of the previous fiscal year thanks to increased volume of mainstay products and effect of price hikes.


- Other / domestic subsidiaries (Domestic subsidiaries, chewing gum, candy, OTC drugs)
 - Net sales increased significantly year on year. There was an impact of the removal of a logistics subsidiary from the scope of consolidation following the transfer of stock for said subsidiary. However, net sales of domestic subsidiaries increased year on year due to increased sales from our sugar trading company and our feed business.
 - Operating profit decreased significantly year on year. In addition to the impact of the removal of the logistics subsidiary, profits decreased at the feed business due to the higher raw material costs.

(2) Pharmaceutical segment

- Net sales increased year on year. Net sales of domestic ethical pharmaceuticals business and overseas ethical pharmaceuticals business increased significantly year on year. Net sales of human vaccines business and veterinary drugs business decreased significantly year on year. Decrease in net sales for veterinary drugs business is due to the impact of transferring agricultural chemicals business that was in the same business category as the veterinary drugs business up to the previous fiscal year.
- Operating profit increased significantly year on year due to the significant increase in sales of domestic ethical pharmaceuticals business and overseas ethical pharmaceuticals business.

(Billions of yen)

For the fiscal year ended March 31	2022	2023	% Change
Net sales	187.9	197.2	4.9%
Operating profit	18.6	21.7	16.4%



Below is an overview of each of pharmaceutical segment's main businesses.

(Billions of yen)

Net sales				Operating profit			
For the fiscal year ended March 31	2022	2023	% Change	For the fiscal year ended March 31	2022	2023	% Change
Domestic ethical pharmaceuticals	90.7	100.1	10.4%	Domestic ethical pharmaceuticals	3.6	10.1	175.8%
Overseas ethical pharmaceuticals	40.3	51.4	27.4%	Overseas ethical pharmaceuticals	4.0	7.7	92.5%
Human vaccines	42.7	34.7	-18.6%	Human vaccines	11.4	2.4	-78.6%
Veterinary drugs*	14.1	10.8	-23.0%	Veterinary drugs*	-0.4	1.4	—

*Up to FYE March 2022, we recorded the agricultural chemicals business, which we transferred in January 2022, in the same business category as the veterinary drugs business. As such, the figures for the veterinary drugs business for FYE March 2022 indicated above include results for the agricultural chemicals business.

■ Domestic ethical pharmaceuticals business

- Net sales increased significantly year on year. Sales of the antibacterial drug *SULBACILLIN* and the anti-allergic drug *BILANOVA* increased.
- Operating profit increased significantly year on year due to sales increase, even though there was an impact of NHI price revisions in Japan. Decrease in R&D expenses also contributed to the increase in profit.

■ Overseas ethical pharmaceuticals business

- Net sales increased significantly year on year, partly due to the positive valuation effect of yen depreciation. Net sales of a subsidiary in India, conducting contract manufacturing for pharmaceuticals, increased. Net sales of a subsidiary in Spain recovered from the results in the previous fiscal year, which was impacted by the COVID-19 pandemic. Royalty revenues also contributed.
- Operating profit increased significantly year on year due to the sales increase and the impact of foreign exchange.

■ Human vaccines business

- Net sales decreased significantly year on year. Despite the largest-ever market supply volume, influenza vaccinations were significantly below assumptions. As a result, the amount of sales returns increased. Also, compare to the previous year, there was no contracted manufacturing income related to AstraZeneca's COVID-19 vaccine formulation.
- Operating profit decreased significantly year on year due to the increase in the amount of sales returns, the decline in contracted manufacturing income related to the COVID-19 vaccine formulation, and the impact of valuation losses on inventories.

■ Veterinary drugs business (Veterinary drugs, veterinary vaccines)

- Net sales decreased significantly year on year. There was an impact of transferring agricultural chemicals business that was in the same business category as the veterinary drugs business up to the previous fiscal year. Excluding this effect, net sales were largely unchanged from the previous fiscal year.
- Operating profit increased year on year. In April 2022, we established Meiji Animal Health Co., Ltd. to integrate the veterinary drug business and the veterinary vaccine business. Benefits of the cost reduction resulting from the business integration contributed.

2) Financial status

(1) Assets, Liabilities, and Net Assets

(Billions of yen)

	As of Mar. 31, 2022	As of Mar. 31, 2023	Change	Main Factors for Change
Current assets	455.6	470.9	15.3	- Raw materials and supplies (+11.6) - Other (+5.6) - Work in process (+1.3) - Cash and deposits (-3.8)
Non-current assets	661.8	665.2	3.4	- Deferred tax assets (+7.2) - Construction in progress (+5.6) - Buildings and structures, net (+4.7) - Investment securities (-11.4) - Land (-3.1)
Total assets	1,117.4	1,136.2	18.7	—
Current liabilities	286.8	266.2	-20.5	- Short-term borrowings (-13.3) - Income taxes payable (-8.8)
Non-current liabilities	117.6	118.6	1.0	- Long-term borrowings (+6.4) - Retirement benefit liability (+1.5) - Other (+2.8) - Bonds payable (-10.0)
Total liabilities	404.4	384.9	-19.5	—
Shareholders' equity	632.8	665.1	32.2	- Retained earnings (+41.8) - Treasury shares (-9.6)
Accumulated other comprehensive income	40.4	46.7	6.3	- Foreign currency translation adjustments (+10.1) - Valuation difference on available-for-sale securities (-4.7)
Minority interests	39.6	39.3	-0.2	—
Total net assets	713.0	751.3	38.2	—
Total liabilities and net assets	1,117.4	1,136.2	18.7	—
Interest bearing debt	81.2	64.3	-16.8	- Short-term borrowings (-13.3)
Equity Ratio (%)	60.3	62.7	2.4pt	—

(2) Status of cash flows

(Billions of yen)

For the fiscal year ended March 31	2022	2023	Change	Main factors for Change
Net cash flow from operating activities	127.5	85.0	-42.5	- Profit before income taxes (-33.0) - Gain on sales of property, plant and equipment (-17.3) - Decrease in contract liability (-10.6) - Loss on tax purpose reduction entry of non-current assets (-8.4) - Increase in inventories (-8.1) - Gain on sales of shares of subsidiaries and associates (+33.5)
Net cash flow from investing activities	-27.6	-36.7	-9.1	- Proceeds from sales of investment securities (-44.2) - Subsidies received (-7.3) - Proceeds from sales of property, plant and equipment and intangible assets (+21.7) - Purchase of property, plant and equipment (+19.5)
Net cash flow from financing activities	-76.9	-54.7	22.2	- Increase in treasury shares (+20.2) - Proceeds from long-term borrowings (+9.7) - Net increase in short-term borrowings (+5.7) - Proceeds from issuance of bonds (-9.9) - Repayments of long-term borrowings (-1.9)
Cash and cash equivalents at end of period	64.8	60.9	-3.9	—
Free cash flow	99.9	48.2	-51.6	—

(3) Status of capital expenditures

Capital expenditures on a cash basis (includes intangible assets) for the current fiscal year were JPY 72.1 billion, with main transactions as indicated below.

- Manufacturing building and infant formula production facilities (Saitama Plant, Meiji Co., Ltd.)
- Drinking milk production facility (Eniwa Plant, Meiji Co., Ltd.)
- Drinking milk and confectionery production facility (Meiji Food (Guangzhou) Co., Ltd.)
- Construction of ice cream factory and introduction of production equipment (Meiji Seika Food Industry (Shanghai) Co., Ltd.)

(4) Transitions in financial benchmarks (consolidated)

For the fiscal year ended March 31	2019	2020	2021	2022	2023
ROE (%)	12.2	12.4	11.1	13.5	10.0
ROA (%)	10.3	10.3	10.7	8.6	6.6
EPS (JPY)	213.30	232.04	226.26	303.62	247.39
D/E ratio (Times)	0.22	0.19	0.16	0.12	0.09

(Note) 1. Calculation Method:

ROE= Net income/Average shareholders' equity

ROA= Ordinary income/Average net assets

EPS= Net income/ (Number of shares outstanding-Number of treasury stock)

D/E ratio= Interest-bearing/Shareholder's equity

2. A two-for-one common stock split was issued on April 1, 2023. EPS is calculated on the assumption that the stock split was conducted at the beginning of the fiscal year ended March 31, 2019.

The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of these materials and reasonable assumptions made by the Company. Actual performance may differ greatly due to a variety of factors.

3) Forecasts for the Fiscal Year ending March 31, 2024

During the fiscal year ending March 2024, which represents the final year of our 2023 Medium-Term Business Plan, we expect the resumption of consumer activities previously curtailed by COVID-19 will drive a recovery in consumer movement and provide an economic boost. However, we forecast earnings will continue to be impacted by domestic prices for raw milk and other raw materials and soaring energy costs.

Accordingly, we revised the initial targets for the Medium-Term Business Plan as follows.

	Results for the fiscal year ended March 31, 2023	Targets for the fiscal year ending March 31, 2024	Initial targets for Medium-Term Business Plan (FYE March 2024)
Meiji ROESG [®]	13.8 point	13 point	13 point
Consolidated net sales	JPY 1,062.1 billion	JPY 1,102.0 billion	JPY 1,080.0 billion
Food segment	JPY 865.6 billion	JPY 887.0 billion	JPY 874.5 billion
Pharmaceutical segment	JPY 197.2 billion	JPY 215.5 billion	JPY 209.0 billion
Consolidated operating profit (margin)	JPY 75.4 billion (7.1%)	JPY 78.0 billion (7.1%)	JPY 120.0 billion (11.1%)
Food segment	JPY 55.8 billion	JPY 56.0 billion	JPY 102.0 billion
Pharmaceutical segment	JPY 21.7 billion	JPY 25.0 billion	JPY 18.5 billion
Overseas net sales	JPY 120.0 billion	JPY 143.0 billion	JPY 134.5 billion
ROIC	6.3%	6.5%	More than 10%
ROE	10.0%	7.0%	More than 11%


Below is an overview of the plan by segment.

(1) Food segment

In Japan, we will raise price to absorb rising raw material and energy costs. We will then work to minimize the impact of price hike on sales volume by enhancing efforts to promote the health value of functional yogurt, yogurt, and health-conscious chocolates. We will also work to expand sales by conducting aggressive marketing activities for sports protein *SAVAS*. At the same time, we will undertake structural reforms, including a review of our production system, to increase profitability.

Overseas, in January 2023, we started operation of Tianjin plant for milk and yogurt to expand production and sales capacity in China. In addition to achieving growth by expanding sales areas, we will expand our line of high value-added products such as functional yogurt and *SAVAS* as we work to foster businesses that will become new growth pillars. In the U.S., we will expand sales channels for our chocolate snacks.

(Billions of yen)			
	Results for the fiscal year ended March 31, 2023	Plan for the fiscal year ending March 31, 2024	% Change
Net sales	865.6	887.0	2.5%
Operating profit	55.8	56.0	0.2%




(2) Pharmaceutical segment

We will focus management resources in the infectious disease domain, as we work to establish a competitive advantage as a top company for vaccines and infectious disease drugs. We are developing inactivated vaccine and next generation mRNA vaccine against COVID-19 using the Group's advanced technologies, facilities, and extensive experience in infectious diseases. We continue working towards early provision. We will manufacture and distribute our influenza vaccines timely, which have the largest market share in Japan. Also, we will strengthen our vaccination awareness efforts.

Overseas, we will focus on strengthening and expanding the CMO/CDMO business. To start commercial production in the new manufacturing building and shipment during FYE March 2024, we will strive for obtaining the necessary approvals. In addition, we work to improve productivity.

(Billions of yen)

	Results for the fiscal year ended March 31, 2023	Plan for the fiscal year ending March 31, 2024	% Change
Net sales	197.2	215.5	9.2%
Operating profit	21.7	25.0	15.1%



4) Basic policy concerning income dividends

As a company mainly involved in food, health, and pharmaceuticals, we are a familiar brand that strives for lifelong engagement with our customers. This means that ensuring a long-term, stable financial platform is critical to our success.

In our 2023 Medium-Term Business Plan, we will promote business management focused on ROIC. We will enhance and improve our business structure towards increasing capital productivity. We will build a firm financial platform by practicing the disciplined distribution of management resources.

We also recognize that appropriate profit returns to our shareholders is a critical management issue. We will increase our dividend payout ratio to around 40% by the end of FYE March 2024. We will also evaluate share repurchasing as necessary based on a careful analysis of numerous factors, including our optimal capital structure and capital surplus.

Furthermore, in the event of significant fluctuations in profit attributable to owners of parent due to extraordinary factors, dividend amounts may be determined after the elimination of those factors.

In the current fiscal year under review, the dividend as of the end of the fiscal period is JPY 95.00 per share. The full-year dividend amount, which includes the dividend paid at the end of the second quarter, will be JPY 180.00 per share, representing a consolidated dividend payout ratio of 36.4%. We increased dividend by JPY 10.00 from the previous fiscal year. We also acquired about JPY 10 billion of treasury shares (about 1.50 million shares, before stock split) to enhance shareholder returns and increase capital efficiency.

Furthermore, to improve the liquidity of the Company's shares, we conducted a two-for-one common stock split on April 1, 2023. On April 3, 2023, we cancelled 3.28 million shares (after stock split) of treasury shares.

For the annual dividend for the fiscal year ending March 31, 2024, we are planning a dividend of JPY 95.00 (JPY 47.50 at end of second quarter and JPY 47.50 at end of fiscal period) (equivalent to JPY 190.00 before the stock split), and forecasting a dividend payout ratio of 52.3%.

2. Fundamental approach to the selection of accounting practices

Our Group is considering the voluntary application of International Financial Reporting Standards (IFRS) with the objective of increasing the ease of cross-border comparisons for financial information on capital markets.

3. Consolidated Financial Statements

1) Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2022	As of March 31, 2023
ASSETS		
Current assets		
Cash and deposits	67,409	63,519
Notes and accounts receivable-trade	173,949	173,001
Merchandise and finished goods	119,316	120,779
Work in process	3,993	5,371
Raw materials and supplies	61,720	73,405
Others	29,307	34,917
Allowance for doubtful accounts	-85	-73
Total current assets	455,611	470,919
Non-current assets		
Property, plants and equipment		
Buildings and structures	354,611	357,771
Accumulated depreciation	-177,532	-175,987
Buildings and structures, net	177,078	181,783
Machinery and equipment	568,092	579,612
Accumulated depreciation	-400,557	-414,059
Machinery and equipment, net	167,534	165,552
Tools, furniture and fixtures	59,013	59,450
Accumulated depreciation	-45,426	-46,731
Tools, furniture and fixtures, net	13,587	12,718
Land	72,594	69,486
Lease assets	2,553	2,522
Accumulated depreciation	-1,844	-1,932
Lease assets, net	709	590
Construction in progress	51,986	57,623
Total property, plants and equipment	483,491	487,755
Intangible assets		
Goodwill	26	11
Other	18,123	21,485
Total intangible assets	18,150	21,496
Investments and other assets		
Investment securities	124,127	112,649
Retirement benefit asset	22,356	21,733
Deferred tax assets	7,166	14,412
Other	6,613	7,313
Allowance for doubtful accounts	-58	-63
Total investments and other assets	160,206	156,046
Total non-current assets	661,848	665,298
Total assets	1,117,459	1,136,217

(Millions of yen)

	As of March 31, 2022	As of March 31, 2023
LIABILITIES		
Current liabilities		
Notes and accounts payable-trade	107,634	112,312
Short-term borrowings	18,227	4,874
Current portion of bonds payable	10,000	10,000
Accrued expenses	31,474	34,994
Income taxes payable	20,141	11,299
Contract liability	5,907	870
Refund liability	15,929	18,052
Provision for bonuses	11,737	11,375
Other	65,759	62,478
Total current liabilities	286,811	266,258
Non-current liabilities		
Bonds payable	20,000	10,000
Long-term borrowings	33,039	39,496
Deferred tax liabilities	5,381	5,497
Retirement benefit liability	54,662	56,255
Provision for retirement benefits for directors (and other officers)	73	76
Other	4,469	7,322
Total non-current liabilities	117,626	118,647
Total liabilities	404,438	384,905
NET ASSETS		
Shareholders' equity		
Share capital	30,000	30,000
Capital surplus	80,503	80,609
Retained earnings	560,238	602,042
Treasury shares	-37,868	-47,502
Total shareholders' equity	632,873	665,149
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	36,347	31,598
Deferred gains or losses on hedges	73	11
Foreign currency translation adjustments	7,673	17,870
Remeasurements of defined benefit plans	-3,631	-2,713
Total accumulated other comprehensive income	40,462	46,767
Non-controlling interests	39,684	39,394
Total net assets	713,021	751,311
Total liabilities and net assets	1,117,459	1,136,217

2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(Millions of yen)

	For the fiscal year ended March 31, 2022	For the fiscal year ended March 31, 2023
Net sales	1,013,092	1,062,157
Cost of sales	689,843	755,354
Gross profit	323,249	306,802
Selling, general and administrative expenses	230,327	231,368
Operating profit	92,922	75,433
Non-operating income		
Interest income	261	390
Dividend income	1,353	1,472
Foreign exchange gains	391	785
Share of profit of entities accounted for using equity method	1,550	—
Subsidy income	493	536
Other	1,337	1,416
Total non-operating income	5,387	4,601
Non-operating expenses		
Interest expenses	500	462
Share of loss of entities accounted for using equity method	—	2,186
Business commencement expenses	422	1,312
Other	3,401	1,913
Total non-operating expenses	4,323	5,875
Ordinary profit	93,985	74,160
Extraordinary income		
Gain on sales of non-current assets	1,981	18,267
Gain on sales of investment securities	3,676	8,052
Gain on sales of shares of subsidiaries and associates	34,680	1,068
Gain on Investments in capital of subsidiaries and associates	—	1,751
Subsidy income	8,913	445
Other	1,528	16
Total extraordinary income	50,780	29,611
Extraordinary losses		
Loss on abandonment of non-current assets	3,239	4,096
Loss on tax purpose reduction entry of non-current assets	8,913	445
Business restructuring expenses	—	3,034
Other	4,157	783
Total extraordinary losses	16,310	8,360
Profit before income taxes	128,455	95,410
Income taxes - current	37,311	29,729
Income taxes - deferred	-1,242	-5,817
Income taxes - total	36,068	23,912
Profit	92,387	71,498
Profit attributable to non-controlling interests	4,890	2,073
Profit attributable to owners of parent	87,497	69,424

(Consolidated Statements of Comprehensive Income)

(Millions of yen)

	For the fiscal year ended March 31, 2022	For the fiscal year ended March 31, 2023
Profit	92,387	71,498
Other comprehensive income		
Valuation difference on available-for-sale securities	2,408	-4,726
Deferred gains or losses on hedges	37	-64
Foreign currency translation adjustments	9,844	5,854
Remeasurements of defined benefit plans, net of tax	2,330	798
Share of other comprehensive income of entities accounted for using equity method	2,000	4,309
Total other comprehensive income	16,620	6,171
Comprehensive income	109,008	77,669
Profit attributable to		
Comprehensive income attributable to owners of parent	103,814	75,729
Comprehensive income attributable to non-controlling interests	5,194	1,940

3) Consolidated Statements of Changes in Net Assets

(Millions of yen)

	For the fiscal year ended March 31, 2022	For the fiscal year ended March 31, 2023
Shareholders' equity		
Share capital		
Balance at the beginning of period	30,000	30,000
Restated balance	30,000	—
Total changes during period	—	—
Balance at the end of period	30,000	30,000
Capital surplus		
Balance at the beginning of period	100,693	80,503
Restated balance	100,693	—
Changes during period		
Disposal of treasury shares	107	138
Cancellation of treasury shares	-22,161	—
Change in ownership interest of parent due to transactions with non-controlling interests	1,863	-32
Total changes during period	-20,190	105
Balance at the end of period	80,503	80,609
Retained earnings		
Balance at the beginning of period	496,766	560,238
Cumulative effects of changes in accounting policies	-342	—
Restated balance	496,423	—
Changes during period		
Dividends of surplus	-23,944	-24,649
Profit attributable to owners of parent company	87,497	69,424
Change in equity in entities accounted for using equity method	—	-2,970
Change of scope of consolidation	262	—
Total changes during period	63,814	41,804
Balance at the end of period	560,238	602,042
Treasury shares		
Balance at the beginning of period	-30,177	-37,868
Restated balance	-30,177	—
Changes during period		
Purchase of treasury shares	-30,014	-10,015
Disposal of treasury shares	161	381
Cancellation of treasury shares	22,161	—
Total changes during period	-7,691	-9,634
Balance at the end of period	-37,868	-47,502

(Millions of yen)

	For the fiscal year ended March 31, 2022	For the fiscal year ended March 31, 2023
Shareholders' equity (cont.)		
Total shareholders' equity		
Balance at the beginning of period	597,282	632,873
Cumulative effects of changes in accounting policies	-342	—
Restated balance	596,940	—
Changes during period		
Dividends of surplus	-23,944	-24,649
Profit attributable to owners of parent company	87,497	69,424
Purchase of treasury shares	-30,014	-10,015
Disposal of treasury stock	269	520
Cancellation of treasury shares	—	—
Change in equity in entities accounted for using equity method	—	-2,970
Change of scope of consolidation	262	—
Change in ownership interest of parent due to transactions with non-controlling interests	1,863	-32
Total changes during period	35,933	32,275
Balance at the end of period	632,873	665,149
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities		
Balance at the beginning of period	33,962	36,347
Restated balance	33,962	—
Changes during period		
Net changes in items other than shareholders' equity	2,385	-4,749
Total changes during period	2,385	-4,749
Balance at the end of period	36,347	31,598
Deferred gains or losses on hedges		
Balance at the end of previous period	37	73
Restated balance	37	—
Changes during period		
Net changes in items other than shareholders' equity	35	-61
Total changes during period	35	-61
Balance at the end of period	73	11
Foreign currency translation adjustments		
Balance at the beginning of period	-4,026	7,673
Restated balance	-4,026	—
Changes during period		
Net changes in items other than shareholders' equity	11,699	10,197
Total changes during period	11,699	10,197
Balance at the end of period	7,673	17,870

(Millions of yen)

	For the fiscal year ended March 31, 2022	For the fiscal year ended March 31, 2023
Accumulated other comprehensive income (cont.)		
Remeasurements of defined benefit plans		
Balance at the beginning of period	-5,828	-3,631
Restated balance	-5,828	—
Changes during the period		
Net changes in items other than shareholders' equity	2,196	918
Total changes during period	2,196	918
Balance at the end of period	-3,631	-2,713
Total accumulated other comprehensive income		
Balance at the beginning of period	24,145	40,462
Restated balance	24,145	—
Changes during the period		
Net changes in items other than shareholders' equity	16,316	6,305
Total changes during period	16,316	6,305
Balance at the end of period	40,462	46,767
Non-controlling interests		
Balance at the beginning of period	37,930	39,684
Restated balance	37,930	—
Changes during the period		
Net changes of items other than shareholders' equity	1,754	-290
Total changes during period	1,754	-290
Balance at the end of period	39,684	39,394
Total net assets		
Balance at the beginning of period	659,358	713,021
Cumulative effects of changes in accounting policies	-342	—
Restated balance	659,016	—
Changes during the period		
Dividends of surplus	-23,944	-24,649
Profit attributable to owners of parent company	87,497	69,424
Purchase of treasury shares	-30,014	-10,015
Disposal of treasury stock	269	520
Cancellation of treasury shares	—	—
Change in equity in entities accounted for using equity method	—	-2,970
Change of scope of consolidation	262	—
Change in ownership interest of parent due to transactions with non-controlling interests	1,863	-32
Net changes in items other than shareholders' equity	18,071	6,014
Total changes during period	54,004	38,290
Balance at the end of period	713,021	751,311

4) Consolidated Statements of Cash Flow

(Millions of yen)

	For the fiscal year ended March 31, 2022	For the fiscal year ended March 31, 2023
Cash flows from operating activities		
Profit before income taxes	128,455	95,410
Depreciation	50,103	53,575
Impairment loss	2,005	257
Amortization of goodwill	15	15
Loss on retirement of property, plants and equipment	3,222	4,086
Loss (gain) on valuation of investment securities	29	—
Increase (decrease) in allowance for doubtful accounts	-98	-16
Increase (decrease) in provision for bonuses	-108	-314
Increase (decrease) in retirement benefit liability	4,407	3,489
Interest and dividend income	-1,614	-1,863
Interest expenses	500	462
Business restructuring expenses	—	3,034
Share of loss (profit) of entities accounted for using equity method	-1,550	2,186
Loss (gain) on sales of property, plant and equipment	-793	-18,143
Loss on tax purpose reduction entry of non-current assets	8,913	445
Loss (gain) on sales of shares of subsidiaries and associates	-34,662	-1,067
Loss (gain) on sales of investment securities	-3,650	-8,038
Loss (gain) on investments in capital of subsidiaries and associates	—	-1,751
Decrease (increase) in trade receivables	2,902	-5,100
Decrease (increase) in inventories	-5,573	-13,721
Increase (decrease) in contract liabilities	5,567	-5,062
Increase (decrease) in trade payables	3,679	9,611
Other, net	5,684	5,223
Subtotal	167,435	122,721
Interest and dividends received	2,339	2,944
Interest paid	-517	-439
Business restructuring expenses paid	—	-2,902
Income taxes paid	-41,730	-37,311
Net cash provided by operating activities	127,526	85,013

(Millions of yen)

	For the fiscal year ended March 31, 2022	For the fiscal year ended March 31, 2023
Cash flows from investing activities		
Purchase of property, plant and equipment	-88,320	-68,811
Purchase of intangible assets	-4,845	-3,359
Proceeds from sales of property, plant and equipment and intangible assets	2,346	24,068
Subsidies received	7,770	454
Purchases of investment securities	-279	-562
Proceeds from sales of investment securities	55,389	11,183
Proceeds from sales of shares of subsidiaries resulting in change in scope of consolidation	2,300	1,944
Proceeds from sales of investments in capital of subsidiaries resulting in change in scope of consolidation	—	919
Other, net	-1,974	-2,625
Net cash used in investing activities	-27,614	-36,788
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	-9,231	-3,450
Proceeds from long-term borrowings	765	10,500
Repayments of long-term borrowings	-12,380	-14,355
Proceeds from issuance of bonds	9,952	—
Redemption of bonds	-10,054	-10,000
Decrease (increase) in treasury shares	-29,754	-9,502
Dividends paid	-23,898	-24,606
Dividends paid to non-controlling interests	-949	-2,230
Other, net	-1,447	-1,090
Net cash provided used in financing activities	-76,997	-54,734
Effect of exchange rate change on cash and cash equivalents	2,931	2,576
Net increase (decrease) in cash and cash equivalents	25,844	-3,933
Cash and cash equivalents at beginning of period	39,011	64,872
Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation	16	—
Cash and cash equivalents at end of period	64,872	60,939

5) Notes Concerning Full-term Financial Statements

(Notes Concerning the Premise of a Going Concern)

Not applicable.

(Changes in Significant Matters That Constitute the Basis for Preparation of Consolidated Financial Statements)

(Changes in scope of consolidation)

(New)

In the FYE March 2023, Meiji Animal Health Co., Ltd. and Meiji Seika Pharmatech Co., Ltd. were added to the scope of consolidation after each establishment as new companies.

(Exclusion)

In the FYE March 2023, KCS Co., Ltd. was removed from the scope of consolidation following the sale of all stock in the company. Meiji Pharma (Shandong) Co., Ltd. was also removed from the scope of consolidation due to the transfer of all of its equity.

(Changes in Accounting Practices)

(Application of Implementation Guidance on Accounting Standard for Fair Market Value Measurement)

As of the beginning of the current consolidated fiscal year under review, we applied the Implementation Guidance on Accounting Standard for Fair Value Measurement (ASBJ Statement No. 31, June 17, 2021, hereinafter, "Implementation Guidance on Fair Value Measurement Accounting Standard"). In accordance with transitional treatment as prescribed in Section 27-2 of the Implementation Guidance on Fair Value Measurement Accounting Standard, we have decided to apply the new accounting practices stipulated by the Implementation Guidance on Fair Value Measurement Accounting Standard prospectively. As such, there is no impact on financial statements for the current consolidated fiscal year under review.

(Changes in method of indication)

(Consolidated Statements of Income)

Subsidy income was included in "Other" under non-operating income for the previous consolidated fiscal year. However, as the monetary significance of this amount increased, we decided to report subsidy income as a separate item from the current consolidated fiscal year. Also, we reported loss on events and compensation expenses under non-operating expenses as separated items. However, as the monetary significance of this amount decreased, we decided to include those items in "Other" under non-operating expenses. Business commencement expenses was included in "Other" under non-operating expenses for the previous consolidated fiscal year. However, as the monetary significance of this amount increased, we decided to report business commencement expenses under non-operating expenses as a separate item from the current consolidated fiscal year. We reported impairment losses under extraordinary losses as a separated item. However, as the monetary significance of this amount decreased, we included impairment losses in "Other" under extraordinary losses from the current consolidated fiscal year.

In order to reflect these changes, the consolidated financial statements for the previous consolidated fiscal year have been reorganized.

As a result, "Other" under non-operating income of JPY 1,830 million is reported as JPY 493 million of subsidy income and JPY 1,337 of "Other". JPY 509 million of loss on events, JPY 426 of compensation expenses and JPY 2,886 million of "Other" under non-operating expenses, are reported as JPY 422 million of business commencement expenses and JPY 3,401 million of "Other". JPY 2,005 million of impairment losses under extraordinary losses and JPY 2,151 million of "Other" is reported as JPY 4,157 million of "Other".

(Additional information)

(Application of the Group Tax Sharing System)

Our Company and some of the consolidated subsidiaries adopted the Group Tax Sharing System from the current consolidated fiscal year.

According to the Practical Solution on the Accounting and Disclosure under the Group Tax Sharing System (Practical solution No. 42 of August 12, 2021), we started to account for and disclose tax effect accounting related to corporate taxes and local income taxes from the previous consolidated fiscal year.

(Segment Information, etc.)

1. Outline of Reporting Segments

The reporting segments of the Meiji Group are the Group's constituent units for which separate financial information is available and for which the Board of Directors regularly conducts examinations to determine the allocation of management resources and evaluate business performance.

The Meiji Group has operating subsidiaries organized based on products/services. Operating subsidiaries develop their business activities by formulating comprehensive strategies for Japan and overseas with respect to their products and services.

Consequently, the Meiji Group consists of segments based on operating subsidiaries, with two reporting segments: Food and Pharmaceutical.

The Food business is handled by Meiji Co., Ltd., and the Pharmaceutical business is handled by Meiji Seika Pharma Co., Ltd. and KM Biologics Co., Ltd.

Each company's main products are as follows.

Segment	Main Products
Food	Yogurt, drinking milk, beverages, cheese, butter, margarine, cream, ice cream, frozen food, chocolate, gummy, chewing gum, sports nutrition, infant formula, enteral formula, beauty supplement, OTC drugs, feedstuffs, sugar and corn sweeteners, etc.
Pharmaceutical	Ethical pharmaceuticals, veterinary drugs, etc.

2. Methods of Calculating Net Sales, Income (Loss), Assets, Liabilities and Other Items for Each Reporting Segment

The accounting treatments for reporting segments are the same as those indicated in Significant Matters That Constitute the Basis for Preparation of Consolidated Financial Statements.

The profit of a reporting segment is the figure for operating income.

Inter-segment sales and transfers are mainly based on the price of third-party transactions, or on manufacturing costs.

3. Information on Net Sales, Income (Loss), Assets, Liabilities and Other Items for Each Reporting Segment
The Previous Consolidated Fiscal Year (April 1, 2021 to March 31, 2022)

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Consolidated Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to Outside Customers	825,451	187,641	1,013,092	–	1,013,092
(2) Inter-segment Sales and Transfers	629	340	969	-969	–
Total	826,080	187,981	1,014,062	-969	1,013,092
Income by Segment	75,973	18,658	94,632	-1,710	92,922
Segment Assets	796,724	327,899	1,124,624	-7,164	1,117,459
Other Items					
Depreciation	40,579	9,300	49,880	223	50,103
Investment in equity-method affiliates	40,471	–	40,471	–	40,471
Increase in property, plants and equipment/intangible assets	79,881	15,409	95,291	191	95,482

(Notes)

1. Details of Adjustments are as follows:

The segment income adjustment of a negative JPY 1,710 million includes inter-segment eliminations of JPY 11 million and a negative JPY 1,721 million in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

The segment assets adjustment of a negative JPY 7,164 million includes inter-segment elimination of a negative JPY 128,707 million and corporate assets of JPY 121,542 million not assigned to respective reporting segments. Major corporate assets include Company (the holding company) surplus investment assets (cash deposits), long-term investment capital (investment securities), and Company-held assets, etc.

2. Segment income is adjusted to the operating income recorded in the quarterly consolidated statements of income.

The Current Consolidated Fiscal Year under Review (April 1, 2022 to March 31, 2023)

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Consolidated Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to Outside Customers	864,894	197,262	1,062,157	–	1,062,157
(2) Inter-segment Sales and Transfers	714	17	732	-732	–
Total	865,609	197,280	1,062,889	-732	1,062,157
Income by Segment	55,874	21,721	77,596	-2,162	75,433
Segment Assets	823,044	326,110	1,149,155	-12,937	1,136,217
Other Items					
Depreciation	43,597	9,745	53,342	233	53,575
Investment in equity-method affiliates	38,826	–	38,826	–	38,826
Increase in property, plants and equipment/intangible assets	41,033	11,283	52,316	214	52,531

(Notes)

1. Details of Adjustments are as follows:

The segment income adjustment of a negative JPY 2,162 million includes inter-segment eliminations of JPY 21 million and a negative JPY 2,184 million in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

The segment assets adjustment of a negative JPY 12,937 million includes inter-segment elimination of a negative JPY 112,239 million and corporate assets of JPY 99,302 million not assigned to respective reporting segments. Major corporate assets include Company (the holding company) surplus investment assets (cash deposits), long-term investment capital (investment securities), and Company-held assets, etc.

2. Segment income is adjusted to the operating income recorded in the quarterly consolidated statements of income.

(Per Share Data)

	Previous Fiscal Year (ended March 31, 2022)	Fiscal Year under Review (ended March 31, 2023)
Net assets per share (JPY)	2,390.76	2,553.69
Net income per share (JPY)	303.62	247.39

(Notes)

1. Diluted net income per share is not given because there are no dilutive shares.
2. A two-for-one common stock split was issued on April 1, 2023. Therefore, net assets per share and net income per share is calculated on the assumption that the stock split was conducted at the beginning of the previous consolidated fiscal year.
3. The basis for calculation of net income per share is as follows.

	Previous Fiscal Year (ended March 31, 2022)	Fiscal Year under Review (ended March 31, 2023)
Basis for calculating profit per share		
Net income attributable to shareholders of parent company (Millions of yen)	87,497	69,424
Amount of profit attributable to owners of parent (Millions of yen)	—	—
Profit attributable to owners of parent of common shareholders (Millions of yen)	87,497	69,424
Average number of common stock outstanding during the year (thousands of share)	288,177	280,633

(Significant subsequent events)

(Notice concerning Stock Split and Subsequent Partial Revision to the Articles of Incorporation)

Meiji Holdings Co., Ltd. (the “Company”) conducted a stock split on April 1, 2023 based on a resolution of Board of Directors Meeting held on November 8, 2022.

1. Purpose of stock split

The purpose of the stock split is to improve its stock liquidity and expand its investor base by lowering the per-share investment price of the Company’s stock.

2. Overview of stock split

(1) Stock split method

The Company conducted a two-for-one stock split of common stock owned by shareholders listed or recorded in the final shareholder register as of March 31, 2023.

(2) Increase in shares due to stock split

Total shares issued prior to stock split:	148,369,500 shares
Increase in shares due to stock split:	148,369,500 shares
Total shares issued following stock split:	296,739,000 shares
Total number of authorized shares following stock split:	1,120,000,000 shares

(3) Schedule for stock split

Publication of record date:	March 15, 2023
Record date:	March 31, 2023
Effective date:	April 1, 2023

(4) Effect on per share information

The effect of the stock split is reflected in the notes to per share information.

3. Subsequent partial revision to the Articles of Incorporation

(1) Reason for the revision to the Articles of Incorporation

Due to this stock split, the total number of authorized shares defined under Article 6 of the Company’s Articles of Incorporation was revised on April 1, 2023, in accordance with Article 184, Paragraph 2 of the Companies Act.

(2) Detail of the revision to the Articles of Incorporation

The detail of the revision is as follow.

(Underlined portion indicates change)

Current Articles of Incorporation	Revised Articles of the Incorporation
(Total number of shares authorized to be issued) Article 6 The total number of shares authorized to be issued by the Company shall be <u>560</u> million shares.	(Total number of shares authorized to be issued) Article 6 The total number of shares authorized to be issued by the Company shall be <u>1,120</u> million shares.

(3) Schedule of the revision to the Articles of Incorporation

Effective date: April 1, 2023

#####

Consolidated Financial Results for Fiscal Year Ended March 31, 2023 - Supplementary Explanatory Data -

Contents

1. Consolidated Financial Results	1
2. Segment Information	4
3. Analysis of Operating Profit	8
4. Consolidated Financial Positions	9
5. Capital Expenditures, Depreciation, R&D Expenses	10
6. Other		
1. [Reference] Food Segment (Non-consolidated) Sales by Main Products	11
2. List of New Products Under Development	12



Meiji Holdings Co., Ltd.

*This document has been translated from the original Japanese as a guide for non-Japanese investors.

*Unaudited figures are included in these materials for reference.

*The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of this presentation and reasonable assumptions made by the Company, and do not represent a commitment from the Company that they will be achieved.

1. Consolidated Financial Results

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

1. Consolidated Operating Results

(Billions of yen)

FYE March 2024	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Net sales	%	%	%	%	%	%	%	%
Cost of sales								
Gross profit								
Selling, general and administrative expenses								
Carriage and storage charges								
Sales promotion expenses								
Labor cost								
Operating profit								
Ordinary profit								
Profit attributable to owners of parent								

Plan -- FYE March 2024					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
544.0	+5.1	558.0	+2.5	1,102.0	+3.8
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
32.0	-25.9	46.0	+42.7	78.0	+3.4
31.5	-28.3	44.0	+45.5	75.5	+1.8
20.0	-40.1	31.0	-14.0	51.0	-26.5

FYE March 2023	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Net sales	247.1	+4.8	48.7	517.5	+3.4	+2.1	798.0	+3.7	75.4	1,062.1	+4.8	+0.4
Cost of sales	174.1	+7.7	—	362.0	+7.6	—	563.2	+9.0	—	755.3	+9.5	—
Gross profit	72.9	-1.6	—	155.4	-5.4	—	234.8	-7.3	—	306.8	-5.1	—
Selling, general and administrative expenses	54.9	-1.1	—	112.2	-1.5	—	170.0	-2.4	—	231.3	+0.5	—
Carriage and storage charges	5.3	+9.7	—	10.0	-2.2	—	14.7	-10.2	—	18.9	-13.6	—
Sales promotion expenses	7.2	-7.9	—	15.7	-5.5	—	25.3	+0.5	—	34.1	+6.2	—
Labor cost	19.3	-2.1	—	38.6	-1.7	—	58.0	-1.6	—	77.7	-0.8	—
Operating profit	18.0	-3.1	44.0	43.1	-14.2	+5.3	64.7	-18.1	83.5	75.4	-18.8	-2.7
Ordinary profit	18.4	-3.5	44.4	43.9	-15.2	+5.8	66.3	-19.1	87.3	74.1	-21.1	-2.4
Profit attributable to owners of parent	16.0	+28.2	51.7	33.3	-8.9	+7.7	47.2	-15.8	76.2	69.4	-20.7	+11.9

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
517.5	+3.4	544.6	+6.3	1,062.1	+4.8
362.0	+7.6	393.3	+11.3	755.3	+9.5
155.4	-5.4	151.3	-4.8	306.8	-5.1
112.2	-1.5	119.0	+2.4	231.3	+0.5
10.0	-2.2	8.8	-23.6	18.9	-13.6
15.7	-5.5	18.3	+18.8	34.1	+6.2
38.6	-1.7	39.1	-0.0	77.7	-0.8
43.1	-14.2	32.2	-24.3	75.4	-18.8
43.9	-15.2	30.2	-28.3	74.1	-21.1
33.3	-8.9	36.0	-29.1	69.4	-20.7

FYE March 2022	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Net sales	235.9	-16.1	46.7	500.7	-14.4	-0.8	769.9	-14.5	76.3	1,013.0	-15.0	+0.4
Cost of sales	161.7	-9.0	—	336.3	-8.7	—	516.6	-8.3	—	689.8	-7.0	—
Gross profit	74.1	-28.3	—	164.3	-24.1	—	253.2	-24.9	—	323.2	-28.1	—
Selling, general and administrative expenses	55.5	-30.9	—	114.0	-31.4	—	174.2	-31.4	—	230.3	-33.0	—
Carriage and storage charges	4.8	-57.2	—	10.2	-55.0	—	16.3	-51.9	—	21.8	-52.0	—
Sales promotion expenses	7.8	-70.1	—	16.6	-70.4	—	25.2	-71.6	—	32.1	-72.8	—
Labor cost	19.7	-1.6	—	39.2	-1.8	—	59.0	-1.7	—	78.4	-1.6	—
Operating profit	18.6	-19.6	36.5	50.3	-0.1	-1.3	79.0	-5.1	87.8	92.9	-12.4	+3.2
Ordinary profit	19.0	-18.8	36.7	51.7	+2.3	-0.4	82.0	-2.7	87.3	93.9	-14.7	-0.0
Profit attributable to owners of parent	12.4	-6.6	40.3	36.6	+27.5	+7.8	56.1	+13.7	66.9	87.4	+33.3	+4.2

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
500.7	-14.4	512.3	-15.6	1,013.0	-15.0
336.3	-8.7	353.4	-5.4	689.8	-7.0
164.3	-24.1	158.9	-31.8	323.2	-28.1
114.0	-31.4	116.3	-34.4	230.3	-33.0
10.2	-55.0	11.6	-49.0	21.8	-52.0
16.6	-70.4	15.4	-74.9	32.1	-72.8
39.2	-1.8	39.1	-1.3	78.4	-1.6
50.3	-0.1	42.5	-23.5	92.9	-12.4
51.7	+2.3	42.1	-29.1	93.9	-14.7
36.6	+27.5	50.8	+37.7	87.4	+33.3

1. Consolidated Financial Results
2. Operating Results of Food Segment

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

(Billions of yen)

FYE March 2024	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Net sales	%	%	%	%	%	%	%	%
Cost of sales								
Gross profit								
Selling, general and administrative expenses								
Carriage and storage charges								
Sales promotion expenses								
Labor cost								
Operating profit								
Ordinary profit								
Profit attributable to owners of parent								

Plan -- FYE March 2024					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
441.4	+4.9	445.6	+0.1	887.0	+2.5
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
25.9	-11.7	30.1	+13.4	56.0	+0.2
25.5	-14.4	28.9	+23.4	54.4	+2.2
18.0	-26.4	18.2	-2.6	36.2	-16.1

FYE March 2023	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Net sales	204.3	+2.3	49.4	420.6	+2.8	+1.6	649.9	+3.8	75.5	865.6	+4.8	+0.5
Cost of sales	151.1	+6.9	—	313.0	+7.8	—	485.6	+9.2	—	650.3	+9.9	—
Gross profit	53.2	-8.9	—	107.6	-9.4	—	164.3	-9.5	—	215.2	-8.0	—
Selling, general and administrative expenses	38.7	-0.8	—	78.2	-1.2	—	119.2	-0.5	—	159.4	+0.8	—
Carriage and storage charges	4.6	+9.1	—	8.6	-3.6	—	12.6	-11.9	—	16.2	-15.1	—
Sales promotion expenses	6.6	-8.7	—	14.2	-6.8	—	23.0	+0.3	—	30.6	+5.8	—
Labor cost	12.9	-2.7	—	25.7	-1.8	—	38.9	-1.3	—	52.4	+0.0	—
Operating profit	14.5	-25.3	42.5	29.3	-25.9	-14.1	45.1	-26.9	75.2	55.8	-26.5	-6.9
Ordinary profit	14.4	-27.1	41.8	29.7	-28.0	-13.7	45.8	-29.1	78.7	53.2	-31.6	-8.7
Profit attributable to owners of parent	13.0	-4.3	47.7	24.4	-16.7	-10.3	35.7	-22.8	79.0	43.1	-20.0	-4.6

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
420.6	+2.8	444.9	+6.7	865.6	+4.8
313.0	+7.8	337.3	+11.8	650.3	+9.9
107.6	-9.4	107.6	-6.6	215.2	-8.0
78.2	-1.2	81.1	+2.8	159.4	+0.8
8.6	-3.6	7.6	-25.2	16.2	-15.1
14.2	-6.8	16.3	+20.0	30.6	+5.8
25.7	-1.8	26.7	+1.8	52.4	+0.0
29.3	-25.9	26.5	-27.1	55.8	-26.5
29.7	-28.0	23.4	-35.6	53.2	-31.6
24.4	-16.7	18.6	-24.0	43.1	-20.0

FYE March 2022	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Net sales	199.8	-18.2	48.8	409.0	-17.6	-0.2	626.3	-17.4	76.0	826.0	-17.4	+0.3
Cost of sales	141.4	-10.6	—	290.2	-10.5	—	444.7	-10.2	—	591.9	-9.2	—
Gross profit	58.4	-32.1	—	118.7	-31.0	—	181.5	-31.1	—	234.1	-32.7	—
Selling, general and administrative expenses	39.0	-37.6	—	79.2	-38.2	—	119.8	-38.7	—	158.1	-39.2	—
Carriage and storage charges	4.3	-60.3	—	8.9	-58.6	—	14.3	-55.6	—	19.1	-55.6	—
Sales promotion expenses	7.3	-69.3	—	15.3	-69.4	—	23.0	-70.6	—	28.9	-72.1	—
Labor cost	13.3	-2.5	—	26.1	-3.2	—	39.4	-3.3	—	52.4	-3.4	—
Operating profit	19.4	-17.5	45.3	39.5	-9.9	-7.7	61.7	-8.9	82.3	75.9	-13.1	+1.3
Ordinary profit	19.7	-14.9	45.0	41.3	-6.0	-6.0	64.7	-5.4	82.4	77.7	-14.9	-1.0
Profit attributable to owners of parent	13.5	-10.0	48.6	29.3	+5.0	+4.8	46.2	+6.1	84.7	53.9	-8.2	-1.2

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
409.0	-17.6	417.0	-17.1	826.0	-17.4
290.2	-10.5	301.6	-7.9	591.9	-9.2
118.7	-31.0	115.3	-34.3	234.1	-32.7
79.2	-38.2	78.9	-40.2	158.1	-39.2
8.9	-58.6	10.2	-52.6	19.1	-55.6
15.3	-69.4	13.6	-74.6	28.9	-72.1
26.1	-3.2	26.2	-3.6	52.4	-3.4
39.5	-9.9	36.3	-16.4	75.9	-13.1
41.3	-6.0	36.3	-23.2	77.7	-14.9
29.3	+5.0	24.6	-20.2	53.9	-8.2

1. Consolidated Financial Results
3. Operating Results of Pharmaceutical Segment

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

(Billions of yen)

FYE March 2024	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Net sales	%	%	%	%	%	%	%	%
Cost of sales								
Gross profit								
Selling, general and administrative expenses								
Carriage and storage charges								
Sales promotion expenses								
Labor cost								
Operating profit								
Ordinary profit								
Profit attributable to owners of parent								

Plan -- FYE March 2024					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
102.9	+5.9	112.6	+12.5	215.5	+9.2
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
7.3	-50.2	17.7	+150.3	25.0	+15.1
6.8	-53.2	17.0	+116.4	23.8	+6.4
2.5	-73.2	12.8	-7.3	15.3	-33.8

FYE March 2023	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Net sales	42.8	+18.3	46.1	97.1	+5.5	+4.5	148.7	+3.0	75.3	197.2	+4.9	-0.1
Cost of sales	23.0	+12.6	—	49.2	+5.8	—	78.0	+7.6	—	105.4	+7.0	—
Gross profit	19.8	+25.7	—	47.9	+5.2	—	70.6	-1.7	—	91.7	+2.7	—
Selling, general and administrative expenses	15.9	-2.4	—	33.2	-3.0	—	49.6	-7.3	—	70.0	-0.9	—
Carriage and storage charges	0.6	+14.9	—	1.3	+7.4	—	2.0	+1.6	—	2.6	-3.1	—
Sales promotion expenses	0.5	+2.7	—	1.4	+9.4	—	2.2	+2.3	—	3.4	+9.6	—
Labor cost	6.0	-1.9	—	12.1	-2.2	—	18.0	-3.1	—	23.8	-3.2	—
Operating profit	3.8	—	49.2	14.6	+29.9	+88.9	21.0	+14.4	105.2	21.7	+16.4	+8.6
Ordinary profit	3.8	—	49.7	14.5	+36.8	+87.9	21.1	+19.0	107.9	22.3	+29.0	+14.1
Profit attributable to owners of parent	2.8	—	68.5	9.3	+24.3	+122.4	12.2	+18.2	81.6	23.1	-32.0	+54.2

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
97.1	+5.5	100.0	+4.4	197.2	+4.9
49.2	+5.8	56.2	+8.0	105.4	+7.0
47.9	+5.2	43.8	+0.2	91.7	+2.7
33.2	-3.0	36.7	+1.0	70.0	-0.9
1.3	+7.4	1.2	-12.5	2.6	-3.1
1.4	+9.4	1.9	+9.7	3.4	+9.6
12.1	-2.2	11.6	-4.3	23.8	-3.2
14.6	+29.9	7.0	-4.2	21.7	+16.4
14.5	+36.8	7.8	+16.5	22.3	+29.0
9.3	+24.3	13.8	-47.9	23.1	-32.0

FYE March 2022	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Net sales	36.2	-2.3	38.0	92.1	+3.3	-3.6	144.4	+0.7	77.3	187.9	-2.9	+0.6
Cost of sales	20.4	+4.0	—	46.5	+4.3	—	72.4	+4.5	—	98.6	+7.9	—
Gross profit	15.7	-9.5	—	45.5	+2.4	—	71.9	-2.9	—	89.3	-12.6	—
Selling, general and administrative expenses	16.3	-7.7	—	34.3	-9.5	—	53.5	-8.2	—	70.6	-14.9	—
Carriage and storage charges	0.5	+2.4	—	1.2	+15.0	—	2.0	+16.3	—	2.7	+14.6	—
Sales promotion expenses	0.5	-77.8	—	1.3	-78.5	—	2.2	-79.0	—	3.1	-77.8	—
Labor cost	6.1	-0.9	—	12.4	-0.3	—	18.6	+0.3	—	24.6	+0.7	—
Operating profit	-0.6	—	—	11.2	+70.6	+32.7	18.3	+16.8	111.4	18.6	-2.3	+13.1
Ordinary profit	-0.9	—	—	10.6	+65.7	+32.6	17.7	+14.2	109.0	17.3	-7.2	+6.4
Profit attributable to owners of parent	-1.2	—	—	7.5	+962.1	+25.0	10.3	+82.0	33.8	33.9	+382.8	+11.1

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
92.1	+3.3	95.8	-8.3	187.9	-2.9
46.5	+4.3	52.1	+11.2	98.6	+7.9
45.5	+2.4	43.7	-24.1	89.3	-12.6
34.3	-9.5	36.3	-19.5	70.6	-14.9
1.2	+15.0	1.4	+14.3	2.7	+14.6
1.3	-78.5	1.8	-77.3	3.1	-77.8
12.4	-0.3	12.2	+1.8	24.6	+0.7
11.2	+70.6	7.3	-40.9	18.6	-2.3
10.6	+65.7	6.7	-45.2	17.3	-7.2
7.5	+962.1	26.4	+318.2	33.9	+382.8

2. Segment Information

1. Food Segment

A. Net Sales

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

(Billions of yen)

FYE March 2024	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
	%	%	%	%	%	%	%	%
Yogurt&cheese								
Nutrition								
Chocolate&gummy								
Drinking milk								
B to B								
Frozen dessert&ready meal								
Overseas								
Other / domestic subsidiaries								

Plan -- FYE March 2024					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
102.3	+2.0	100.7	-1.4	203.1	+0.3
63.2	+6.2	59.5	+4.0	122.8	+5.1
44.3	+1.7	58.8	-0.7	103.1	+0.3
39.4	+7.0	36.6	+5.5	76.0	+6.3
36.8	+12.1	39.6	+3.4	76.4	+7.4
33.2	+2.9	27.3	+6.1	60.5	+4.4
40.7	+28.6	46.7	+26.9	87.5	+27.7
81.2	-2.6	76.0	-16.2	157.2	-9.7

FYE March 2023	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Yogurt&cheese	50.2	-7.5	46.1	100.3	-6.8	-7.9	151.5	-4.9	73.9	202.5	-3.5	-1.2
Nutrition	28.9	+5.8	48.0	59.5	+5.9	-1.3	90.6	+5.4	77.2	116.8	+6.6	-0.5
Chocolate&gummy	22.0	+5.5	49.9	43.5	+3.6	-1.3	75.2	+4.8	72.6	102.8	+4.9	-0.7
Drinking milk	17.8	-8.6	47.2	36.8	-7.4	-2.5	54.6	-6.6	74.6	71.5	-6.1	-2.2
B to B	16.0	+10.6	50.3	32.8	+7.8	+2.9	53.2	+7.2	76.1	71.1	+8.2	+1.8
Frozen dessert&ready meal	14.4	+0.1	45.8	32.2	-0.2	+1.9	45.6	-0.7	78.1	57.9	-0.5	-0.7
Overseas	13.9	+21.1	49.7	31.7	+26.5	+12.7	49.9	+30.3	72.7	68.5	+30.3	-0.2
Other / domestic subsidiaries	40.7	+9.5	57.4	83.4	+10.6	+17.5	129.0	+10.6	78.2	174.1	+11.8	+5.5

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
100.3	-6.8	102.1	+0.0	202.5	-3.5
59.5	+5.9	57.2	+7.4	116.8	+6.6
43.5	+3.6	59.2	+5.9	102.8	+4.9
36.8	-7.4	34.7	-4.7	71.5	-6.1
32.8	+7.8	38.2	+8.5	71.1	+8.2
32.2	-0.2	25.7	-0.9	57.9	-0.5
31.7	+26.5	36.8	+33.8	68.5	+30.3
83.4	+10.6	90.6	+12.9	174.1	+11.8

FYE March 2022	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Yogurt&cheese	54.3	—	—	107.6	—	—	159.4	—	—	209.7	—	—
Nutrition	27.4	—	—	56.2	—	—	86.0	—	—	109.6	—	—
Chocolate&gummy	20.8	—	—	42.0	—	—	71.7	—	—	98.0	—	—
Drinking milk	19.4	—	—	39.7	—	—	58.4	—	—	76.1	—	—
B to B	14.5	—	—	30.5	—	—	49.6	—	—	65.8	—	—
Frozen dessert&ready meal	14.4	—	—	32.3	—	—	45.9	—	—	58.2	—	—
Overseas	11.5	—	—	25.0	—	—	38.3	—	—	52.6	—	—
Other / domestic subsidiaries	37.2	—	—	75.4	—	—	116.6	—	—	155.7	—	—

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
107.6	—	102.1	—	209.7	—
56.2	—	53.3	—	109.6	—
42.0	—	55.9	—	98.0	—
39.7	—	36.4	—	76.1	—
30.5	—	35.2	—	65.8	—
32.3	—	25.9	—	58.2	—
25.0	—	27.5	—	52.6	—
75.4	—	80.3	—	155.7	—

2. Segment Information

1. Food Segment

B. Operating Profit

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

(Billions of yen)

FYE March 2024	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
	%	%	%	%	%	%	%	%
Yogurt&cheese								
Nutrition								
Chocolate&gummy								
Drinking milk								
B to B								
Frozen dessert&ready meal								
Overseas								
Other / domestic subsidiaries								

Plan -- FYE March 2024					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
13.1	+9.6	12.0	-0.4	25.2	+4.6
9.1	+5.6	7.7	+30.8	16.9	+15.9
2.1	-32.9	8.9	+13.0	11.1	-0.3
-1.8	—	-1.1	—	-3.0	—
1.7	+73.3	2.4	+19.0	4.2	+36.7
2.6	-3.2	0.9	+89.8	3.6	+11.3
-2.0	—	-0.3	—	-2.4	—
0.9	-61.1	-0.5	—	0.3	-89.8

FYE March 2023	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Yogurt&cheese	6.1	-39.0	36.1	12.0	-35.7	-29.1	16.9	-36.4	64.6	24.1	-30.9	-8.0
Nutrition	4.1	-14.4	42.6	8.6	-18.8	-11.3	12.8	-23.5	82.4	14.6	-24.5	-6.1
Chocolate&gummy	2.6	+23.0	68.5	3.2	-14.0	-15.1	8.8	-7.9	74.5	11.1	-11.8	-5.3
Drinking milk	-0.3	—	—	-0.8	—	—	-1.7	—	—	-2.5	—	—
B to B	0.4	+36.0	37.6	1.0	+18.1	-18.1	2.2	-3.4	76.1	3.0	+12.8	+6.5
Frozen dessert&ready meal	0.7	+38.7	30.4	2.7	+15.9	+14.3	3.1	+13.8	93.2	3.2	+10.1	-4.0
Overseas	-0.4	—	—	0.0	-71.0	—	-0.2	—	—	-0.9	—	—
Other / domestic subsidiaries	1.1	-22.5	84.7	2.3	-22.0	+70.3	3.0	-28.5	102.3	3.0	-38.9	+2.7

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
12.0	-35.7	12.1	-25.5	24.1	-30.9
8.6	-18.8	5.9	-31.5	14.6	-24.5
3.2	-14.0	7.9	-10.8	11.1	-11.8
-0.8	—	-1.6	—	-2.5	—
1.0	+18.1	2.0	+10.4	3.0	+12.8
2.7	+15.9	0.5	-13.4	3.2	+10.1
0.0	-71.0	-1.0	—	-0.9	—
2.3	-22.0	0.7	-63.1	3.0	-38.9

FYE March 2022	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Yogurt&cheese	10.0	-35.2	39.8	18.7	-28.6	-25.9	26.6	-26.7	77.6	34.9	-26.7	+1.8
Nutrition	4.8	+18.1	48.7	10.6	+13.6	+7.1	16.7	+20.2	87.4	19.3	+9.0	+0.9
Chocolate&gummy	2.1	+33.2	70.7	3.7	+62.5	+25.4	9.5	+18.8	75.6	12.6	+8.0	+0.2
Drinking milk	-0.0	—	—	-0.0	—	—	-0.2	—	—	-0.7	—	—
B to B	0.3	—	119.9	0.8	+540.0	+200.6	2.2	+59.4	74.3	2.7	+52.1	-11.0
Frozen dessert&ready meal	0.5	-65.3	22.1	2.3	-28.0	-0.4	2.7	-21.0	90.8	2.9	-19.0	-3.3
Overseas	0.1	-58.9	—	0.2	-51.0	—	-0.3	—	—	-1.0	—	—
Other / domestic subsidiaries	1.4	+13.9	63.8	2.9	+10.6	+27.5	4.2	+5.3	86.8	5.0	+5.0	+2.0

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
18.7	-28.6	16.2	-24.4	34.9	-26.7
10.6	+13.6	8.6	+3.8	19.3	+9.0
3.7	+62.5	8.9	-5.4	12.6	+8.0
-0.0	—	-0.6	—	-0.7	—
0.8	+540.0	1.8	+13.2	2.7	+52.1
2.3	-28.0	0.5	+64.1	2.9	-19.0
0.2	-51.0	-1.3	—	-1.0	—
2.9	+10.6	2.0	-2.2	5.0	+5.0

2. Segment Information
2. Pharmaceutical Segment
A. Net Sales

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

(Billions of yen)

FYE March 2024	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Domestic ethical pharmaceuticals	%	%	%	%	%	%	%	%
Overseas ethical pharmaceuticals								
Human vaccines								
Veterinary drugs								

Plan -- FYE March 2024					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
48.9	+2.9	62.5	+18.8	111.4	+11.2
28.3	+12.9	27.2	+3.1	55.5	+7.9
20.5	+6.5	17.3	+11.3	37.8	+8.6
5.2	-2.6	5.6	+1.1	10.8	-0.7

FYE March 2023	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Domestic ethical pharmaceuticals	23.1	+32.6	51.3	47.5	+11.3	+5.2	73.5	+10.4	74.0	100.1	+10.4	+0.8
Overseas ethical pharmaceuticals	12.7	+20.9	59.8	25.0	+29.7	+17.6	38.9	+33.5	75.0	51.4	+27.4	-0.9
Human vaccines	4.3	-4.8	21.8	19.2	-15.3	-2.8	28.1	-24.5	79.4	34.7	-18.6	-1.8
Veterinary drugs	2.6	-28.7	39.1	5.3	-27.4	-20.4	8.0	-29.0	74.9	10.8	-23.0	+0.8

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
47.5	+11.3	52.6	+9.6	100.1	+10.4
25.0	+29.7	26.3	+25.3	51.4	+27.4
19.2	-15.3	15.5	-22.4	34.7	-18.6
5.3	-27.4	5.5	-18.3	10.8	-23.0

FYE March 2022	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Domestic ethical pharmaceuticals	17.4	—	—	42.7	—	—	66.5	—	—	90.7	—	—
Overseas ethical pharmaceuticals	10.5	—	—	19.3	—	—	29.1	—	—	40.3	—	—
Human vaccines	4.5	—	—	22.7	—	—	37.2	—	—	42.7	—	—
Agricultural chemicals&veterinary drugs	3.6	—	—	7.3	—	—	11.3	—	—	14.1	—	—

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
42.7	—	48.0	—	90.7	—
19.3	—	21.0	—	40.3	—
22.7	—	20.0	—	42.7	—
7.3	—	6.7	—	14.1	—

Note: As we transferred the agricultural chemical business in January 2022, we changed "Agricultural chemicals&veterinary drugs" to "Veterinary drugs" from FYE March 2023.

YoY changes of FYE March 2023 are calculated compared to the results of FYE March 2022 including the agricultural chemical business.

2. Segment Information
2. Pharmaceutical Segment
B. Operating Profit

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

(Billions of yen)

FYE March 2024	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Domestic ethical pharmaceuticals	%	%	%	%	%	%	%	%
Overseas ethical pharmaceuticals								
Human vaccines								
Veterinary drugs								

Plan -- FYE March 2024					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
0.8	-85.2	12.2	+157.2	13.0	+28.1
2.2	-39.9	3.0	-25.9	5.2	-32.5
4.1	-14.8	2.1	—	6.2	+153.3
0.2	-74.1	0.4	-38.3	0.6	-57.8

FYE March 2023	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Domestic ethical pharmaceuticals	2.0	—	99.8	5.4	+205.7	+157.3	9.3	+201.6	123.2	10.1	+175.8	+33.5
Overseas ethical pharmaceuticals	1.9	+1,266.5	109.3	3.6	+195.5	+103.3	6.2	+116.2	85.1	7.7	+92.5	+4.1
Human vaccines	-0.6	—	—	4.8	-44.5	+45.9	4.8	-62.9	130.9	2.4	-78.6	-33.8
Veterinary drugs	0.4	—	80.6	0.7	—	+54.6	0.5	—	40.9	1.4	—	+9.4

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
5.4	+205.7	4.7	+148.1	10.1	+175.8
3.6	+195.5	4.0	+46.4	7.7	+92.5
4.8	-44.5	-2.3	—	2.4	-78.6
0.7	—	0.6	—	1.4	—

FYE March 2022	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Domestic ethical pharmaceuticals	-0.7	—	—	1.7	—	-1.8	3.1	+33.3	155.3	3.6	-34.3	+83.9
Overseas ethical pharmaceuticals	0.1	-88.0	6.9	1.2	-43.7	-41.0	2.9	+4.8	62.0	4.0	+5.4	-14.8
Human vaccines	0.3	—	8.5	8.6	+70.2	+111.7	13.0	+17.6	121.9	11.4	+18.0	+7.0
Agricultural chemicals&veterinary drugs	-0.3	—	—	-0.4	—	—	-0.6	—	—	-0.4	—	—

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
1.7	—	1.9	-68.1	3.6	-34.3
1.2	-43.7	2.7	+72.9	4.0	+5.4
8.6	+70.2	2.7	-39.9	11.4	+18.0
-0.4	—	-0.0	—	-0.4	—

Note: As we transferred the agricultural chemical business in January 2022, we changed "Agricultural chemicals&veterinary drugs" to "Veterinary drugs" from FYE March 2023.

YoY changes of FYE March 2023 are calculated compared to the results of FYE March 2022 including the agricultural chemical business.

3. Analysis of Operating Profit


(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

1. Results -- FYE March 2023

(Billions of yen)

	Q1				Q1-Q2				Q1-Q3				Full-year			
	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other
Results -- FYE March 2022	18.6	19.4	-0.6	-0.1	50.3	39.5	11.2	-0.5	79.0	61.7	18.3	-1.0	92.9	75.9	18.6	-1.7
Due to increased/decreased sales	+4.8	+0.4	+4.4	—	+7.3	+1.8	+5.5	—	+11.4	+6.5	+4.9	—	+20.4	+13.7	+6.7	—
Impact of drug price revision	-1.2	—	-1.2	—	-2.3	—	-2.3	—	-3.6	—	-3.6	—	-5.0	—	-5.0	—
Changes in costs of goods sold	-2.8	-2.9	+0.1	—	-7.6	-7.7	+0.1	—	-14.8	-14.9	+0.1	—	-22.4	-22.7	+0.3	—
Changes in other SG&A expenses	-0.6	-1.0	+0.4	—	-0.6	-2.7	+2.1	—	-1.1	-6.7	+5.6	—	-5.5	-9.9	+4.4	—
Other (incl. change in results of subsidiaries)	-0.8	-1.4	+0.7	-0.1	-4.0	-1.7	-2.0	-0.2	-6.2	-1.5	-4.3	-0.3	-4.9	-1.1	-3.4	-0.4
Total change	-0.5	-4.9	+4.4	-0.1	-7.1	-10.2	+3.3	-0.2	-14.2	-16.5	+2.6	-0.3	-17.4	-20.0	+3.0	-0.4
Results -- FYE March 2023	18.0	14.5	3.8	-0.2	43.1	29.3	14.6	-0.7	64.7	45.1	21.0	-1.4	75.4	55.8	21.7	-2.1

YoY Change in Operating Profit



(Breakdown)

- *1: [Food] Increase in raw materials costs: -23.2, Other: +0.5
[Pharma] Cost reductions: +0.3
- *2: [Food] Increase in indirect manufacturing costs (incl. energy costs): -5.2,
Increase in marketing expenses: -3.3, Other: -1.4
[Pharma] Decrease in R&D expenses: +2.9
Decrease in marketing expenses (incl. impacts of structural reforms): +2.4,
Other: -0.9

2. Plan -- FYE March 2024

(Billions of yen)

	H1 (Q1-Q2)				H2 (Q3-Q4)				Full-year			
	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other
Results -- FYE March 2023	43.1	29.3	14.6	-0.7	32.2	26.5	7.0	-1.3	75.4	55.8	21.7	-2.1
Due to increased/decreased sales	+23.8	+26.4	-2.6	—	+32.9	+23.2	+9.7	—	+56.7	+49.6	+7.1	—
Impact of drug price revision	-1.6	—	-1.6	—	-1.8	—	-1.8	—	-3.4	—	-3.4	—
Changes in costs of goods sold	-19.6	-18.8	-0.8	—	-12.4	-11.9	-0.5	—	-32.0	-30.7	-1.3	—
Changes in other SG&A expenses	-9.8	-8.6	-1.2	—	-5.3	-8.1	+2.8	—	-15.1	-16.7	+1.6	—
Other (incl. change in results of subsidiaries)	-3.9	-2.4	-1.1	-0.4	+0.2	+0.3	+0.3	-0.4	-3.7	-2.1	-0.8	-0.8
Total change	-11.1	-3.4	-7.3	-0.4	+13.7	+3.5	+10.6	-0.4	+2.5	+0.1	+3.2	-0.8
Plan -- FYE March 2024	32.0	25.9	7.3	-1.2	46.0	30.1	17.7	-1.8	78.0	56.0	25.0	-3.0

4. Consolidated Financial Positions

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

(Billions of yen)

FYE March 2023	As of Jun. 30		As of Sep. 30		As of Dec. 31		As of Mar. 31	
		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end
		%		%		%		%
Total assets	1,144.3	+2.4	1,183.8	+5.9	1,214.9	+8.7	1,136.2	+1.7
Current assets	481.1	+5.6	508.1	+11.5	540.4	+18.6	470.9	+3.4
Non-current assets	663.2	+0.2	675.7	+2.1	674.4	+1.9	665.2	+0.5
Total liabilities	418.9	+3.6	426.8	+5.5	466.8	+15.4	384.9	-4.8
Current liabilities	302.1	+5.4	306.9	+7.0	356.6	+24.4	266.2	-7.2
Non-current liabilities	116.8	-0.7	119.9	+1.9	110.1	-6.4	118.6	+0.9
Total net assets	725.3	+1.7	757.0	+6.2	748.1	+4.9	751.3	+5.4
Shareholders' equity	636.1	+0.5	654.0	+3.3	645.9	+2.1	665.1	+5.1

Reference	Consolidated interest bearing debt	117.9	+45.1	116.2	+43.0	138.9	+71.0	64.3	-20.8
	Food segment assets	795.7	-0.1	823.6	+3.4	843.9	+5.9	823.0	+3.3
	Pharmaceutical segment assets	318.0	-3.0	330.8	+0.9	330.2	+0.7	326.1	-0.5

FYE March 2022	As of Jun. 30		As of Sep. 30		As of Dec. 31		As of Mar. 31	
		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end
		%		%		%		%
Total assets	1,097.5	+2.9	1,144.9	+7.3	1,161.5	+8.9	1,117.4	+4.7
Current assets	453.9	+6.6	480.6	+12.8	494.1	+16.0	455.6	+6.9
Non-current assets	643.5	+0.4	664.2	+3.6	667.3	+4.1	661.8	+3.3
Total liabilities	433.7	+6.4	449.2	+10.2	465.0	+14.1	404.4	-0.8
Current liabilities	278.6	+10.1	293.9	+16.2	309.7	+22.4	286.8	+13.4
Non-current liabilities	155.0	+0.3	155.2	+0.4	155.2	+0.4	117.6	-23.9
Total net assets	663.7	+0.7	695.7	+5.5	696.4	+5.6	713.0	+8.1
Shareholders' equity	599.0	+0.3	623.5	+4.4	620.6	+3.9	632.8	+6.0

Reference	Consolidated interest bearing debt	151.7	+49.1	130.2	+27.9	128.6	+26.4	81.2	-20.2
	Food segment assets	743.4	-1.6	771.1	+2.1	798.5	+5.7	796.7	+5.5
	Pharmaceutical segment assets	268.1	-6.4	292.8	+2.3	295.4	+3.1	327.8	+14.5

5. Capital Expenditures, Depreciation, R&D Expenses

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

(Billions of yen)

	FYE March 2021		FYE March 2022		FYE March 2023		Plan -- FYE March 2024	
	H1 (Q1-Q2)	Full-year	H1 (Q1-Q2)	Full-year	H1 (Q1-Q2)	Full-year	H1 (Q1-Q2)	Full-year
Capital expenditures	33.2	67.9	48.0	93.1	33.5	72.1	32.1	62.8
Food segment	28.3	56.4	38.3	75.9	29.6	63.4	24.5	47.4
Pharmaceutical segment	4.8	11.3	9.5	17.0	3.7	8.5	7.3	14.9
Holdings	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.4
Depreciation and amortization	23.6	48.4	24.5	50.1	26.1	53.5	27.2	54.3
Food segment	19.0	39.2	19.8	40.5	21.2	43.5	22.4	44.8
Pharmaceutical segment	4.4	8.9	4.5	9.3	4.8	9.7	4.6	9.2
Holdings	0.1	0.2	0.1	0.2	0.1	0.2	0.1	0.3
R&D expenses	14.4	31.4	15.5	33.4	14.6	30.9	18.1	37.6
Food segment	6.5	13.1	6.4	13.3	6.7	13.6	7.2	14.9
Pharmaceutical segment	7.6	17.6	8.6	19.2	7.4	16.3	10.2	21.4
Holdings	0.2	0.5	0.3	0.8	0.5	0.9	0.6	1.3

Note: The figures of "Capital expenditures" and "Depreciation and amortization" include "Intangible assets."

Note: We changed the previous classification "Corporate or elimination" to "Holdings" when we announced the financial results for fiscal year ended March 2022 on May 12, 2022.

Accordingly, we retroactively revised the figures of depreciation in "Pharmaceutical segment" and "Holdings".

6. Other

1. [Reference] Food Segment (Non-consolidated) Sales by Main Products [Before applying revenue recognition standards]

(Amounts appearing in the tables below have been rounded off to nearest 100 million yen)

(Billions of yen)

FYE March 2024	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Yogurt	%	%	%	%	%	%	%	%
Probiotic yogurts								
Cheese for consumers								
Chocolate								
Infant formula and enteral formula								
Sports nutrition (incl. SAVAS Milk Protein)								
Drinking milk for consumers (incl. home delivery)								
Ice cream for consumers								

Plan -- FYE March 2024					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
40.1	+0.6	37.3	+3.0	77.4	+1.8
49.1	+8.6	51.2	+1.9	100.2	+5.1
13.7	+1.9	14.5	-1.6	28.2	+0.1
42.3	+5.9	61.6	+3.9	103.8	+4.7
34.3	+2.9	34.0	+0.2	68.3	+1.6
25.4	+6.6	22.1	+3.2	47.5	+5.0
37.8	+1.5	34.6	-1.3	72.4	+0.2
27.0	+5.7	16.5	+2.8	43.5	+4.6

FYE March 2023	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Yogurt	19.9	-6.1	46.5	39.9	-6.0	-6.9	58.0	-6.9	75.7	76.1	-6.9	-0.7
Probiotic yogurts	22.8	-9.8	45.3	45.2	-8.8	-10.3	70.2	-4.9	72.1	95.4	-2.7	-2.1
Cheese for consumers	6.8	-9.5	49.9	13.5	-8.8	-0.8	21.3	-5.7	76.2	28.2	-3.1	+0.9
Chocolate	20.5	+3.5	49.8	39.9	+1.0	-3.0	71.3	+2.4	71.1	99.1	+3.0	-1.1
Infant formula and enteral formula	16.3	+11.7	51.9	33.4	+8.2	+6.3	51.7	+5.3	76.9	67.3	+5.9	+0.1
Sports nutrition (incl. SAVAS Milk Protein)	11.8	+0.6	44.5	23.8	+2.2	-10.2	35.6	+3.8	78.3	45.2	+5.7	-0.7
Drinking milk for consumers (incl. home delivery)	17.9	-9.5	47.2	37.2	-8.0	-1.8	55.1	-7.1	75.9	72.3	-6.3	-0.4
Ice cream for consumers	11.0	+6.2	44.6	25.6	+3.5	+3.5	33.7	+2.4	81.8	41.6	+3.5	+0.9

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
39.9	-6.0	36.2	-7.9	76.1	-6.9
45.2	-8.8	50.2	+3.6	95.4	-2.7
13.5	-8.8	14.7	+2.8	28.2	-3.1
39.9	+1.0	59.2	+4.3	99.1	+3.0
33.4	+8.2	33.9	+3.8	67.3	+5.9
23.8	+2.2	21.4	+9.8	45.2	+5.7
37.2	-8.0	35.0	-4.4	72.3	-6.3
25.6	+3.5	16.1	+3.4	41.6	+3.5

FYE March 2022	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Yogurt	21.2	-5.9	49.6	42.4	-4.4	-0.7	62.4	-3.0	76.0	81.8	-3.1	-0.3
Probiotic yogurts	25.3	-16.8	45.8	49.5	-12.4	-10.2	73.8	-12.3	75.4	98.0	-12.5	+0.2
Cheese for consumers	7.5	-4.9	49.2	14.8	-3.8	-3.0	22.5	-5.5	76.6	29.1	-6.4	-1.3
Chocolate	19.8	+2.8	48.6	39.5	+3.5	-3.0	69.6	+0.6	72.1	96.3	+0.3	-0.3
Infant formula and enteral formula	14.6	-1.1	48.7	30.8	+2.8	+2.9	49.0	+8.3	78.1	63.5	+8.1	+1.1
Sports nutrition (incl. SAVAS Milk Protein)	11.7	+30.9	47.4	23.3	+12.1	-5.9	34.3	+10.6	77.4	42.8	+5.6	-3.6
Drinking milk for consumers (incl. home delivery)	19.8	-10.2	48.4	40.4	-10.7	-0.9	59.3	-10.4	77.4	77.1	-10.3	+0.6
Ice cream for consumers	10.4	-9.8	41.1	24.7	-7.0	-2.1	33.0	-4.4	81.6	40.2	-3.9	-0.4

H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
42.4	-4.4	39.3	-1.7	81.8	-3.1
49.5	-12.4	48.4	-12.6	98.0	-12.5
14.8	-3.8	14.3	-9.0	29.1	-6.4
39.5	+3.5	56.8	-1.8	96.3	+0.3
30.8	+2.8	32.7	+13.5	63.5	+8.1
23.3	+12.1	19.5	-1.2	42.8	+5.6
40.4	-10.7	36.7	-9.8	77.1	-10.3
24.7	-7.0	15.5	+1.6	40.2	-3.9

6. Other

2. List of New Products Under Development

Infectious disease

Stage	Name	Type	Efficacy Classification	Notes
Phase III (Multinational study including Japan)	OP0595 (Nacubactam)	Injection	β -lactamase inhibitor	Discovered in-house Multi-Regional Clinical Trials

New fields

Stage	Name	Type	Efficacy Classification	Notes
Filed (Under review, South Korea) Phase III	ME3208 (Belumosudil)	Oral	Chronic Graft Versus Host Disease	Development: Romeck Pharma, LLC
In preparation for application (Overseas)* Phase I**	DMB-3115	Injection	Plaque psoriasis/Psoriatic arthritis/Crohn's disease/Ulcerative colitis (Biosimilar)	*Co-development: Dong-A Socio Holdings Co., Ltd. (South Korea) *Out-license: Intas Pharmaceuticals Ltd. (India) **Co-development: Dong-A Socio Holdings Co., Ltd. (South Korea)
Phase III (Multinational study including Japan)	HBI-8000 (Tucidinostat)	Oral	Unresectable or metastatic melanoma	Co-development: HUYABIO International, LLC (USA) Multi-Regional Clinical Trial
Phase II (Overseas)	ME3183	Oral	Psoriasis/Selective PDE4 inhibitor	Discovered in-house
Phase Ib / II	HBI-8000 (Tucidinostat)	Oral	Relapsed or refractory B-cell non-Hodgkin's lymphoma	In-license: HUYABIO International, LLC (USA)

Human vaccines

Stage	Name	Target Disease	Notes
Filed (Under review)	KD-370	Pentavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, and haemophilus influenza type b	
Filed (Under review) Phase III	ARCT-154	Next generation mRNA vaccine against COVID-19	Partnership: CSL Seqirus (Australia)
Phase III (Adults under 40)* Phase III (Pediatric Clinical Trials) Phase II / III Phase II / III (Pediatric Clinical Trials) Phase I / II	KD-414	Inactivated vaccine against COVID-19	* Multi-Regional Clinical Trials
Phase I (Overseas)	KD-382	Quadrivalent vaccine against dengue fever	
Phase I	KD2-396	Hexavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, haemophilus influenza type b, and Hepatitis B virus	

Blood Plasma Products

Stage	Name	Target Disease	Notes
Approved	KD2-305	Suppression of bleeding tendency in patients with blood coagulation factor VIII or factor IX deficiency who have coagulation factor inhibitors	Discovered in-house

Note: The above list shows development status as of May 11, 2023.